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ABSTRACT 
This project evaluated the attitudes of psychiatric patients towards receiving either 
olanzapine or the first-generation antipsychotic agents. Newly admitted patients to 
a state psychiatric hospital who were either prescribed olanzapine (n=35) or other 
first-generation antipsychotic agents (n=34) were compared on measure of their 
personal attitudes toward receiving medicines using the Drug Attitude Inventory 
(DAI). Subjects were evaluated prior to receiving olanzapine and 8 weeks later 
unless they were discharged or discontinued sooner. The olanzapine-treated group 
recorded significantly greater improvements on their positive attitude scores toward 
taking the medicine, and reduced negative attitude scores relative to the comparator 
group. These results remained statistically significant even after correction of baseline 
differences between the two groups for the positive attitudes and a statistical trend 
persisted for negative attitude scores too. During the subsequent 30 month 
follow-up, significantly fewer of the olanzapine treated subjects (5, 14.3%) were 
readmitted to the hospital compared with 13 (38.2%) of the comparator group. 
_ These data suggest switching patients to olanzapine may improve their attitudes 
towards taking medicines at least in the short-term. These preliminary data need 
affirmation or refutation in a controlled random-assignment longer-term clinical trial 
where specific measures of adherence are evaluated, and where the comparators 
are the other second generation antipsychotic agents. 
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INTRODUCTION 
The attitudes of psychiatric patients 
towards receiving medicines, may be crucial 
in long term adherence to treatment (Lacro 
et al, 2002; Loffler, et al., 2003). Due to 
the higher acquisition costs of newer 
antipsychotic medicines, the hospital 
administration was interested in evaluating 
the initial use of olanzapine by psychiatrists 
at a state psychiatric hospital, and so this 
project was done as a quality assurance 
project. The patients' attitudes towards 
receiving antipsychotic medicines were 
evaluated for two treatment groups as noted 
in the methods section of this paper. The 
study was approved by the Research Review 
Board of Mayview State Hospital and the 
Office of Mental Health and Substance 
Abuse Services of the Commonwealth of 
Pennsylvania and also by the University of 
Pittsburgh Institutional Review Board as an 
exempt from consent study. The data were 
first deidentified of all personal identifiers 
by a volunteer, and then provided to the 
research team for analyses. 
METHODS 
Patients 
Adult patients are admitted to Mayview 
State Hospital after failing to improve 
adequately at a community psychiatric 
hospital where they would have usually 
spent up to 4 weeks, and require extended 
inpatient psychiatric care. Such patients are 
transferred to die state run psychiatric 
facility. 
The group treated with olanzapine was 
evaluated once the attending psychiatrist 
had decided to use olanzapine on a clinical 
basis for patients with schizophrenia, 
schizoaffective disorder or bipolar I disorder. 
None of these subjects had previously 
received olanzapine. The comparator group 
included those subjects who received first 
generation antipsychotic agents and were 
not switched to another agent at the time 
of study enrollment or through the period 
of the project. The comparator group was 
similar with respect to the approximate date 
of admission (± 1 week) and diagnosis as 
for the olanzapine treated group, as were 
other demographic and illness characteristics, 
(see Table 1). Subjects chosen for olanzapine 
were based on the prescribing doctor's 
clinical choice and patient agreement, and 
so diis was not a random assignment study. 
Assessments 
The quality assurance assessment for die 
subjects was the 10-item Drug Attitude 
Inventory (DAI) (Awad et al, 1995; Hogan, 
1983). 
The staff member who obtained die 
Drug Attitude Inventory questionnaire was 
blind to whether the subject was receiving 
olanzapine or not. Furthermore, the staff 
member was not a member of the team diat 
later authored this paper. Nonetheless, it 
is important to note that the DAI is a 
patient self-report. Assessments were 
conducted at baseline and again at 8 weeks. 
If the subjects were discharged from die 
hospital or were discontinued from 
olanzapine sooner than 8 weeks, assessments 
were done at that time point. 
Statistics 
The baseline demographic and clinical 
variables between the two treatment groups 
were evaluated using either the Pearson's 2 
test or Fishers Exact Test for categorical 
data or the independent sample "t" test for 
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TABLE I : Demography and Illness Characteristics of the Study Cohort I 
Age in Years 
Mean + SD 
Gender M/F 
Ethnicity - Caucasian/African American/Asian 
DSM IV Diagnosis 
Schizophrenia 
Schizoaffective Disorder-Depressed Type 
Schizoaffective Disorder-Bipolar Type 
Bipolar 1 Mania 
Age at (Inset (Hospitalization) 
Mean Years + SD 
Length of Illness 
Mean Years + SD 
Number of Previous Hospitalizations 
Mean + SD 
41.5 + 9 
19/16 
' 25/10/0 
21 
9 
3 
2 
23.1 + 7 
17.6 + 9 
13.6 + 15.7 
42.4 + 12 
16/18 
23/9/2 
22 
8 
3 
1 
22.9 + 8 
17.5 + 10 
10.4 + 6 
INone of the demographic or illness characteristics were statistically significantly different 
between the two treatment groups. 
normally distributed continuous data. 
Between group comparisons for continuous 
data were evaluated using the independent 
sample "t" test. All analyses were accepted 
for statistical significance at a two-sided 
alpha level of 0.05, and a trend between 
0.05 and 0.10. 
RESULTS 
Patient Demography and Illness 
Characteristics 
The study cohort comprised of 69 
subjects, 35 subjects received olanzapine 
and 34 subjects received the first-generation 
antipsychotic agents. (See Table 1). Data 
from one comparator subject could not be 
obtained after the baseline assessments and 
was hence excluded. The mean age for the 
group was nearly 42 years, and the DSM 
IV (American Psychiatric Association, 1994) 
diagnoses were schizophrenia (n = 43), 
schizoaffective disorder (n=23), and bipolar 
1 disorder (n=3). Nearly, a third of the 
group was of African American ethnicity, 
and nearly half of the subjects were women. 
The age at onset (first hospitalization) and 
the duration of illness were similar in both 
Olanzapine Group Comparator Group 
(n=35) (n=34) 
groups, and both groups had been 
hospitalized frequendy. The mean daily 
maximum dose of olanzapine was 15.2 mg 
(SD 5.4, range 5 to 20 mg), and the 
comparator group received 937 mg (SD 
648) chlorpromazine equivalents daily (Davis 
et al, 1983). These first generation 
antipsychotic agents included haloperidol, 
thiothixene, trifluoperazine, perphenazine and 
thioridazine. The patients (bipolar and 
schizoaffective disorder) receiving either 
lithium or divalproex sodium as mood-
stabilizers continued to receive those agents 
unchanged in dosage, and similarly the 
subjects receiving antidepressants continued 
those agents unchanged. 
Drug Attitude Inventory (DAI) 
(see Table 2) 
The olanzapine-treated group recorded a 
lower mean positive attitude score and a 
higher mean negative attitude score than the 
comparator group at baseline (t=-2.95, 
df=65, p=0.004, and t = -2.90, df = 65, 
p = 0.005, respectively). At the Week 8 
ratings, the olanzapine-treated group had 
statistically significant improvements in the 
mean positive attitude scores compared to 
the control group (t=2.4, df=60, p=0.02), 
and this difference remained significant 
when statistically corrected for differences 
in the baseline scores. The percentage change 
from baseline in the positive attitude score 
for the olanzapine treated group was 25.5% 
whereas it was only 3.6% for the comparator 
group (see Figure 1). Similar results were 
obtained for the negative attitude scores 
towards the medication with the olanzapine-
treated group experiencing statistically 
significant decreases (i.e. improvement) as 
compared to the comparator group at 8 
weeks (t=-2.3, df=65, p=0.03), and a 
statistical trend persisted when corrected 
for baseline differences (t=-1.89, df=65, 
p=0.065). The percentage change from 
baseline in the negative attitude score for 
the olanzapine treated group was 22.6% 
whereas it was only 4.5% for the comparator 
group. 
All patients were discharged from the 
hospital, and the number of subjects who 
were re-admitted to the facility in a 30-
month period were enumerated. Five (14.3%) 
of the 35 olanzapine treated subjects and 
thirteen (38.2%) of the 34 subjects treated 
with the first generation agents were re-
admitted (Fisher's exact test, p = 0.03). 
One of the reasons noted for re-admission > 
in nearly all the eighteen charts was "non-
compliance", and over half the charts also 
noted alcohol or drug abuse-dependence (n 
= 9) as possible contributing factors. Side-
effects such as excessive weight gain, 
extrapyramidal side-effects or others were 
not specifically reported in the charts, and 
the re-admitted patients were not specifically 
evaluated again for their attitudes towards 
taking medicines. 
DISCUSSION 
This study suggested patients had 
improved positive attitude and lower negative 
attitude scores after they began olanzapine 
treatment. Ostensibly, this positive attitude 
could lead to longer-term medication 
adherence by patients though this issue was 
not specifically assessed in this study. 
Nonetheless, a surrogate marker was the 
rate of re-hospitalization, which was 
significandy lower in the olanzapine treated 
group. The lack of insight, or the occurrence 
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TABLE 2 : DAI Ratings and Hospital Privileges at Baseline and Week 8* 
Rating Scale  Olanzapine 
Baseline 8 Weeks 
n=35 n=33 
Comparator Group 
Baseline 8 Weeks 
n=34 n=31 
DAI 
Positive Attitude 
Negative Attitude 
4.7 + 1.4a 
5.3 + 1.3a 
5.9 + 1.5b 
4.1 + 1.5b 
5.6 + 1.4 
4.4 + 1.5 
5.8 + 1.5 
4.2 + 1.5 
At baseline, the group that later received olanzapine had higher mean negative attitude scores and 
lower mean positive attitude scores towards taking their medication as compared to the control 
group. 
p<0.05 change from baseline scores favoring olanzapine over the control group. After correction 
for baseline differences, the statistical significance for the positive attitude scores persisted for the 
olanzapine group, and a trend was noted for the negative attitude scores in favor of the olanzapine 
group. 
* A few subjects in each group had missing scores at the 2 time points, (n = 2 in the olanzapine, 
n = 3 in the comparator group. 
FIGURE I : Present Improvement in Scores on Positive and Negative Attitudes 
(DAI) of Patients receiving Either Olanzapine or First Generation Antipsychotic 
Agents 
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of the side-effects of first generation 
antipsychotic agents such as akathisia, 
Parkinsonian side-effects, or tardive 
dyskinesia, or the lack of efficacy are 
among several factors why patients may not 
like the medicines they receive, and this is 
likely to impact on long term adherence to 
treatment (Loffler et al., 2003). The 
discontinuation of antipsychotic medications 
and severe relapses and re-hospitalization is 
all too familiar to most clinicians. In a 
follow-up period of 30 months, significandy 
fewer olanzapine treated subjects were re-
hospitalized in this study though 
unfortunately their attitudes towards 
medicines were not assessed long term or 
at readmission. 
The limitations of this study include a 
non-randomized design, a small sample size, 
the first generation antipsychotic agents 
were lumped together as one class and 
finally, the positive and negative attitude 
scores were unequal between the groups at 
baseline, no comparisons were conducted 
with other second-generation antipsychotic 
agents. At the initiation of this quality 
assurance project, only risperidone was 
available as a first line newer antipsychotic 
agent. Clozapine was reserved for treatment 
refractory or neuroleptic intolerant patients. 
Also, it is possible that a longer study design 
may have noted that some subjects gain 
substantial weight on olanzapine treatment, 
and this may have impacted on overall 
adherence to treatment. As this study was 
not a random assignment clinical trial, it is 
entirely possible that patients being switched 
to a newer agent such as olanzapine were 
dissatisfied with their previous treatment, 
and so the medication change may have led 
to an expectation that conditions would get 
better, and so they rated themselves positively 
when they were switched to olanzapine. 
This argument has merit, as the negative 
attitude scores of those subjects who were 
switched to olanzapine were in fact greater 
than their counterparts who were not 
switched. 
In spite of these limitations, it may be 
useful to consider switching to antipsychotic 
agents that patients may favor taking on 
their own and without overt or covert 
coercion. In the context of the doctor-
patient relationship, it may be crucial to 
remember there is no way to tell, whether 
an oral drug is either effective or not, or 
causes side effects until the patient actually 
takes the prescribed medicine. Put another 
way, the patients' preference and attitudes 
to taking a particular medicine is very 
important. Consequently, as clinicians we 
would be well advised to discuss with 
patients their personal attitudes and 
preferences towards different medicines e%-en 
if it means that some patients will readily 
prefer to take 'no medicines' at all. 
In summary, subjects switched to 
olanzapine treatment at a state psychiatric 
hospital recorded improved attitudes toward 
taking medication as compared to those 
who were treated with the first generation 
agents. These results are similar to the data 
of another naturalistic study conducted in 
Spain that compared olanzapine, risperidone 
and haloperidol monotherapy (Garcia-Cabeza 
(I53) CHENGAPPA et al 
et al, 2001). Olanzapine treated subjects 
achieved significantly higher DAI positive 
attitude scores than those treated with either 
risperidone or haloperidol (Garcia-Cabeza et 
al, 2(H)1) Finally, improved attitudes toward 
taking olanzapine may result in greater long 
term adherence though this needs to be 
tested in a controlled randomized clinical 
trial with specific adherence measures. 
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